Earnings summaries and quarterly performance for Sotera Health.
Executive leadership at Sotera Health.
Board of directors at Sotera Health.
AK
Ann Klee
Detailed
Director
CS
Christopher Simon
Detailed
Director
CM
Constantine Mihas
Detailed
Director
DW
David Wheadon
Detailed
Director
JN
James Neary
Detailed
Director
KF
Karen Flynn
Detailed
Director
RK
Robert Knauss
Detailed
Director
RC
Ruoxi Chen
Detailed
Director
SC
Sean Cunningham
Detailed
Director
VP
Vincent Petrella
Detailed
Lead Independent Director
Research analysts who have asked questions during Sotera Health earnings calls.
Brett Fishbin
KeyBanc Capital Markets
5 questions for SHC
Also covers: ALC, COO, ICUI +6 more
Michael Polark
Wolfe Research
5 questions for SHC
Also covers: BSX, DXCM, EMBC +11 more
Patrick Donnelly
Citi
5 questions for SHC
Also covers: A, AVTR, BIO +21 more
DW
David Windley
Jefferies Financial Group Inc.
4 questions for SHC
Also covers: CERT, CNC, CRL +14 more
Jason Bednar
Piper Sandler Companies
4 questions for SHC
Also covers: ALGN, COO, EDAP +15 more
Luke Sergott
Barclays
4 questions for SHC
Also covers: A, AVTR, BRKR +19 more
CW
Casey Woodring
JPMorgan Chase & Co.
3 questions for SHC
Also covers: A, BLLN, CRL +10 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for SHC
Also covers: A, ADPT, AVTR +21 more
Sean Dodge
RBC Capital Markets
2 questions for SHC
Also covers: CDMO, CTLT, EVH +10 more
Dave Windley
Jefferies LLC
1 question for SHC
Also covers: CERT, CNC, ELV +7 more
Recent press releases and 8-K filings for SHC.
Sotera Health Provides Business Overview and Financial Targets
SHC
Guidance Update
Revenue Acceleration/Inflection
Debt Issuance
- Sotera Health is a global leader in sterilization and lab testing, with 70%+ of revenue tied to multi-year contracts and a diversified business across three segments: Sterigenics, Nordion, and Nelson Labs.
- The company has delivered sustained revenue growth for over 20 years, achieving a 9% CAGR since 2005.
- For the 2025-2027 period, Sotera Health targets an Organic Revenue Growth CAGR of 5% - 7% and an Organic Adjusted EBITDA Growth CAGR of 5-8%, along with a margin improvement target of 50-150bps.
- As of September 30, 2025, the company reported Net Revenues of $860,176 thousand and Adjusted EBITDA of $436,764 thousand for the nine months ended, with a Net Leverage Ratio of 3.3x.
- Sotera Health is on track with its Investor Day commitments as of September 30, 2025, including achieving 6.2% organic revenue growth and 10.4% Adjusted EBITDA growth year-to-date.
3 days ago
Sotera Health Provides Business Update at J.P. Morgan Healthcare Conference
SHC
Guidance Update
Revenue Acceleration/Inflection
Legal Proceedings
- Sotera Health (SHC) expects 2025 revenues to surpass $1.16 billion , aligning with its long-term guidance (2025-2027) of 5%-7% top-line growth and 5%-8% Adjusted EBITDA growth.
- Through Q3 2025, the company achieved 6.2% organic growth, 10.4% Adjusted EBITDA growth, and 195 basis points of margin improvement.
- The capital structure has improved, with net leverage reduced by one turn to 3.3 times and debt maturity extended to 2031.
- Improving demand is noted in the Sterigenics business, with inventory issues largely resolved across most med device and pharma categories.
- Favorable legal outcomes in Georgia led to the dismissal of bellwether cases , and one significant customer plans to outsource sterilization to SHC, with effects anticipated from late 2026 into 2027-2028.
3 days ago
Sotera Health Provides 2025 Revenue Update and Long-Term Outlook
SHC
Guidance Update
Legal Proceedings
New Projects/Investments
- Sotera Health expects 2025 revenue to surpass $1.16 billion, reflecting over 5% growth, with all three businesses performing well in Q4 2025.
- The company reaffirmed its long-term guidance for 5%-7% top-line growth and 5%-8% EBITDA growth from 2025 through 2027, with organic growth tracking at 6.2% through Q3 2025.
- Sotera Health anticipates 3%-4% price increases for the total company in 2026 and is expanding capacity with an X-ray facility opening in 2026 and cobalt development programs expecting first harvest in 2028.
- In legal proceedings, three bellwether cases in Georgia were dismissed due to lack of causation, and the company is confident in its defense for California trials scheduled for January 2027 and April 2027.
3 days ago
Sotera Health Provides Business Update and Financial Outlook
SHC
Guidance Update
New Projects/Investments
Legal Proceedings
- Sotera Health announced that 2025 revenue surpassed $1.16 billion, reflecting over 5% growth.
- The company is on track with its 2025-2027 long-range guide, reporting 6.2% organic growth, 10.4% adjusted EBITDA growth, and 195 basis points of margin improvement through Q3 2025, with a target of $500 million-$600 million in cumulative free cash flow over the period.
- Capital structure has improved, with the net leverage ratio at 3.3 times and debt maturity extended to 2031.
- Significant investments are underway for Cobalt-60 development, with the first harvest expected in 2028, and new Sterigenics greenfield facilities opening in 2026 and late 2027/early 2028.
- Ethylene oxide regulations (NESHAP) have been extended to April 2028, and favorable rulings in Georgia resulted in the dismissal of three bellwether cases, while California litigation trials are set for January and April 2027.
3 days ago
Sotera Health provides preliminary 2025 revenue guidance
SHC
Earnings
Guidance Update
- Sotera Health expects its full-year 2025 revenue to surpass $1.16 billion, representing an increase of at least 5.5% year over year, or 5.0% on a constant-currency basis.
- This projected revenue growth would mark over two decades of year-over-year revenue growth for the company.
- The company plans to release its full-year 2025 results and 2026 outlook on February 24, 2026.
- These financial figures are preliminary estimates and are subject to the completion of year-end closing procedures and audit.
4 days ago
Sotera Health Provides Business Update and 2025 Revenue Expectations
SHC
Guidance Update
Revenue Acceleration/Inflection
- Sotera Health is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
- The company anticipates its revenue to exceed $1.16 billion in 2025, representing an increase of at least 5.5% year-over-year, or 5.0% on a constant-currency basis.
- This projected revenue growth marks over two decades of year-over-year revenue growth for Sotera Health.
- Sotera Health plans to release its full-year results and 2026 outlook on February 24, 2026.
- The financial information provided for 2025 consists of preliminary estimates, and actual results may vary upon completion of financial statement closing procedures.
4 days ago
SHC Discusses Sterilization Market Dynamics, Financial Targets, and Litigation
SHC
Legal Proceedings
New Projects/Investments
Guidance Update
- The sterilization market is approximately two-thirds outsourced, with SHC expecting to maintain 3%-4% annual price gains despite new capacity coming online.
- New NSHAP regulations, extended beyond April 2026, are prompting some customers to outsource sterilization, including one significant customer transitioning volume to SHC from late 2026 into 2027/2028.
- SHC projects CapEx to decrease after 2026, following investments in cobalt development and NSHAP compliance, with maintenance CapEx around $60 million +/- $10 million.
- The company targets reducing net leverage from 3.3x to 2x-3x by the end of 2027, while aiming for 5%-7% top-line growth and $500-$600 million in free cash flow between 2025-2027.
- SHC remains confident in its Nordion business, which boasts 60% margins, and believes it has de-risked EO litigation, citing favorable outcomes when science is presented in court.
Dec 3, 2025, 4:00 PM
Sotera Health Discusses Strategic Priorities and Financial Outlook
SHC
Guidance Update
New Projects/Investments
Legal Proceedings
- Sotera Health (SHC) anticipates 3%-4% price increases annually for the total company, with its Sterigenics segment at the higher end, noting that sterilization costs are typically less than 5% of customer product costs.
- The company aims to reduce its net leverage from 3.3x to a target range of 2-3x by the end of 2027, projecting $500-$600 million in free cash flow generation between 2025 and 2027, alongside a goal of 5%-7% top-line growth.
- CapEx is currently elevated due to cobalt development and $200 million in NSHAP compliance investments over multiple years, but is expected to decrease, with maintenance CapEx anticipated to be around $60 million ± $10 million.
- SHC plans to bring one new facility online next year and another in late 2027/early 2028, typically aiming to secure 40% of capacity with customer commitments before commencing construction.
- The company highlights its Nordion business as a strong asset with 60%+ margins, being the sole global Cobalt-60 player and fully integrated in the supply chain.
Dec 3, 2025, 4:00 PM
Sotera Health Outlines Growth, Capital Allocation, and Regulatory Impact
SHC
Guidance Update
New Projects/Investments
Legal Proceedings
- Sotera Health aims to achieve 2-3x net leverage by the end of 2027, targeting 5-7% top-line growth and $500-$600 million in free cash flow between 2025 and 2027.
- The company plans to bring one new facility online next year and another in late 2027 (potentially 2028), typically securing 40% of capacity commitments before construction.
- CapEx is currently elevated due to cobalt development and approximately $200 million for NSHAP compliance, but is projected to decline towards a maintenance level of around $60 million +/- $10 million.
- New NSHAP regulations for ethylene oxide sterilizers, though extended beyond April 2026, are challenging, leading one significant customer to transition their in-house sterilization to Sotera Health starting in late 2026.
- Sotera Health expects to maintain 3-4% annual price increases across the company, with Sterigenics at the higher end, given that sterilization represents less than 5% of customer product costs.
Dec 3, 2025, 4:00 PM
Sotera Health Reports Strong Q3 Performance and Outlines 2025-2027 Growth Outlook
SHC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Sotera Health reported Q3 2025 top line growth of 9% and adjusted EBITDA growth of 12.2%, with year-to-date top line growth of 6% and adjusted EBITDA growth of 10%.
- The company projects organic top line growth of 5-7% and bottom line growth of 5-8% for 2025-2027, expecting $500 million-$600 million in free cash flow over this three-year period.
- Sotera Health is focused on capital allocation for organic growth, including investments in new X-ray facilities and cobalt-60 development, while maintaining approximately $900 million in liquidity and working to reduce its 3.3 times net leverage.
- The company's three core businesses, Sterigenics, Nordion, and Nelson Labs, have organic growth targets ranging from low single digits to high single digits, with Nelson Labs experiencing significant margin expansion.
Nov 19, 2025, 1:30 PM
Quarterly earnings call transcripts for Sotera Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more